Table 1. Open in new tab...

Baseline characteristic	SMT	STPP + SMT	p
Sex [male] [%]	18 [64.3]	18 [64.3]	1
Age [years] (mean [SD])	17.50 [2.98]	14.69 [2.80]	<0.01
BMI [kg/m²] (mean [SD])	19.15 [6.27]	16.75 [8.54]	0.23
Disease duration [months] (mean [SD])	40.71 [32.29]	18.93 [20.67]	<0.01
IBD type [%]			1
CD	10 [35.7]	11 [37.9]
UC	18 [64.3]	18 [62.1]
Surgical resection [%]	1 [3.6]	2 [6.9]	1
Medication
5-ASA [%]	13 [46.4]	15 [51.7]	0.89
AZA [%]	5 [17.9]	2 [6.9]	0.39
Steroid [%]	0 [0.0]	0 [0.0]	NA
Biologics [%]	6 [21.4]	7 [24.1]	1
Previous therapeutic lines^a [%]	2.5 [1.2]	2.3 [1.3]	0.43
Steroid naïve^b [%]	7 [23.3]	9 [30]	0.61
Previous flares^c [%]			0.23
1	14 [46.6]	19 [63.3]
2	2 [6.7]	0
Steroid cycles^d [%]			0.58
1	9 [30]	10 [33]
3	0	1 [3.3]
Baseline psychological symptoms
Depressive symptoms [PHQ-9] (mean [SD])	6.9 [4.7]	7.7 [4.4]	0.64
PHQ-9 ≥10 [%]	7 [25]	13 [44.8]	0.12
Anxiety symptoms [GAD-7] (mean [SD])	7.3 [5.8]	8 [5]	0.50
GAD-7 ≥10 [%]	8 [28.6]	8 [27.6]	0.93
Previous psychotropic medication [%]^e	2 [7.1]	0 [0.0]	0.47

Baseline characteristic

SMT

STPP + SMT

n = 30

Sex [male] [%]

18 [64.3]

Age [years] (mean [SD])

17.50 [2.98]

14.69 [2.80]

<0.01

BMI [kg/m²] (mean [SD])

19.15 [6.27]

16.75 [8.54]

0.23

Disease duration [months] (mean [SD])

40.71 [32.29]

18.93 [20.67]

<0.01

IBD type [%]

10 [35.7]

11 [37.9]

18 [64.3]

18 [62.1]

Surgical resection [%]

1 [3.6]

2 [6.9]

Medication

5-ASA [%]

13 [46.4]

15 [51.7]

0.89

AZA [%]

5 [17.9]

2 [6.9]

0.39

Steroid [%]

0 [0.0]

Biologics [%]

6 [21.4]

7 [24.1]

Previous therapeutic lines^a [%]

2.5 [1.2]

2.3 [1.3]

0.43

Steroid naïve^b [%]

7 [23.3]

9 [30]

0.61

Previous flares^c [%]

0.23

14 [46.6]

19 [63.3]

2 [6.7]

Steroid cycles^d [%]

0.58

9 [30]

10 [33]

1 [3.3]

Baseline psychological symptoms

Depressive symptoms [PHQ-9] (mean [SD])

6.9 [4.7]

7.7 [4.4]

0.64

PHQ-9 ≥10 [%]

7 [25]

13 [44.8]

0.12

Anxiety symptoms [GAD-7] (mean [SD])

7.3 [5.8]

8 [5]

0.50

GAD-7 ≥10 [%]

8 [28.6]

8 [27.6]

0.93

Previous psychotropic medication [%]^e

2 [7.1]

0 [0.0]

0.47

Baseline characteristic	SMT	STPP + SMT	p
Sex [male] [%]	18 [64.3]	18 [64.3]	1
Age [years] (mean [SD])	17.50 [2.98]	14.69 [2.80]	<0.01
BMI [kg/m²] (mean [SD])	19.15 [6.27]	16.75 [8.54]	0.23
Disease duration [months] (mean [SD])	40.71 [32.29]	18.93 [20.67]	<0.01
IBD type [%]			1
CD	10 [35.7]	11 [37.9]
UC	18 [64.3]	18 [62.1]
Surgical resection [%]	1 [3.6]	2 [6.9]	1
Medication
5-ASA [%]	13 [46.4]	15 [51.7]	0.89
AZA [%]	5 [17.9]	2 [6.9]	0.39
Steroid [%]	0 [0.0]	0 [0.0]	NA
Biologics [%]	6 [21.4]	7 [24.1]	1
Previous therapeutic lines^a [%]	2.5 [1.2]	2.3 [1.3]	0.43
Steroid naïve^b [%]	7 [23.3]	9 [30]	0.61
Previous flares^c [%]			0.23
1	14 [46.6]	19 [63.3]
2	2 [6.7]	0
Steroid cycles^d [%]			0.58
1	9 [30]	10 [33]
3	0	1 [3.3]
Baseline psychological symptoms
Depressive symptoms [PHQ-9] (mean [SD])	6.9 [4.7]	7.7 [4.4]	0.64
PHQ-9 ≥10 [%]	7 [25]	13 [44.8]	0.12
Anxiety symptoms [GAD-7] (mean [SD])	7.3 [5.8]	8 [5]	0.50
GAD-7 ≥10 [%]	8 [28.6]	8 [27.6]	0.93
Previous psychotropic medication [%]^e	2 [7.1]	0 [0.0]	0.47

Table 1.

Open in new tab

Sociodemographic characteristics of participants at baseline.

Baseline characteristic	SMT	STPP + SMT	p
Baseline characteristic	n = 30	n = 30	p
Sex [male] [%]	18 [64.3]	18 [64.3]	1
Age [years] (mean [SD])	17.50 [2.98]	14.69 [2.80]	<0.01
BMI [kg/m²] (mean [SD])	19.15 [6.27]	16.75 [8.54]	0.23
Disease duration [months] (mean [SD])	40.71 [32.29]	18.93 [20.67]	<0.01
IBD type [%]			1
CD	10 [35.7]	11 [37.9]
UC	18 [64.3]	18 [62.1]
Surgical resection [%]	1 [3.6]	2 [6.9]	1
Medication
5-ASA [%]	13 [46.4]	15 [51.7]	0.89
AZA [%]	5 [17.9]	2 [6.9]	0.39
Steroid [%]	0 [0.0]	0 [0.0]	NA
Biologics [%]	6 [21.4]	7 [24.1]	1
Previous therapeutic lines^a [%]	2.5 [1.2]	2.3 [1.3]	0.43
Steroid naïve^b [%]	7 [23.3]	9 [30]	0.61
Previous flares^c [%]			0.23
1	14 [46.6]	19 [63.3]
2	2 [6.7]	0
Steroid cycles^d [%]			0.58
1	9 [30]	10 [33]
3	0	1 [3.3]
Baseline psychological symptoms
Depressive symptoms [PHQ-9] (mean [SD])	6.9 [4.7]	7.7 [4.4]	0.64
PHQ-9 ≥10 [%]	7 [25]	13 [44.8]	0.12
Anxiety symptoms [GAD-7] (mean [SD])	7.3 [5.8]	8 [5]	0.50
GAD-7 ≥10 [%]	8 [28.6]	8 [27.6]	0.93
Previous psychotropic medication [%]^e	2 [7.1]	0 [0.0]	0.47

Baseline characteristic	SMT	STPP + SMT	p
Baseline characteristic	n = 30	n = 30	p
Sex [male] [%]	18 [64.3]	18 [64.3]	1
Age [years] (mean [SD])	17.50 [2.98]	14.69 [2.80]	<0.01
BMI [kg/m²] (mean [SD])	19.15 [6.27]	16.75 [8.54]	0.23
Disease duration [months] (mean [SD])	40.71 [32.29]	18.93 [20.67]	<0.01
IBD type [%]			1
CD	10 [35.7]	11 [37.9]
UC	18 [64.3]	18 [62.1]
Surgical resection [%]	1 [3.6]	2 [6.9]	1
Medication
5-ASA [%]	13 [46.4]	15 [51.7]	0.89
AZA [%]	5 [17.9]	2 [6.9]	0.39
Steroid [%]	0 [0.0]	0 [0.0]	NA
Biologics [%]	6 [21.4]	7 [24.1]	1
Previous therapeutic lines^a [%]	2.5 [1.2]	2.3 [1.3]	0.43
Steroid naïve^b [%]	7 [23.3]	9 [30]	0.61
Previous flares^c [%]			0.23
1	14 [46.6]	19 [63.3]
2	2 [6.7]	0
Steroid cycles^d [%]			0.58
1	9 [30]	10 [33]
3	0	1 [3.3]
Baseline psychological symptoms
Depressive symptoms [PHQ-9] (mean [SD])	6.9 [4.7]	7.7 [4.4]	0.64
PHQ-9 ≥10 [%]	7 [25]	13 [44.8]	0.12
Anxiety symptoms [GAD-7] (mean [SD])	7.3 [5.8]	8 [5]	0.50
GAD-7 ≥10 [%]	8 [28.6]	8 [27.6]	0.93
Previous psychotropic medication [%]^e	2 [7.1]	0 [0.0]	0.47

N = 60 [n = 30 for each condition]. SD = standard deviation; SMT = standard medical therapy; STPP = short-term psychodinamic psychotherapy; BMI = body mass index; PHQ-9 = patient health questionnaire; GAD-7 = generalised anxiety disorder; AZA = Azathioprine; 5-ASA = 5-aminosalicylic acid (Mesalamine).

^a,b,c,dRefers to the 52 weeks preceding the baseline.

^eReflects the number and percentage of participants answering ‘yes’ to this question [including two youths treated with anxiolytic medication 4 years before baseline assessment].

This Feature Is Available To Subscribers Only